Healthcare / BiotechnologyNasdaqCM
$0.75
-0.03 (-3.85%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-17.9M · quality 52.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
5/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$8M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-203.8%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2016–2025 · 9 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.94x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-16.2M · FCF $-15.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | — | — | — | — | — | $0.00 | $0.00 | — | $0.00 | $0.00 | $0.00 |
| Net Income | $-16.2M | $-16.2M | $-21.1M | $-30.9M | $-23.7M | $-20.7M | $-17.9M | $-10.7M | $-12.4M | $-3.3M | $-4.1M |
| EBITDA | $-15.5M | $-15.5M | $-21.1M | $-31.0M | $-23.8M | — | — | — | — | — | — |
| EPS | -17.40 | -17.40 | -266.89 | -22.56 | -990.00 | -880.00 | — | — | — | — | — |
| Balance Sheet | |||||||||||
| Current Ratio | 5.61 | 5.61 | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||
| Free Cash Flow | $-15.3M | $-15.3M | $-17.9M | $-24.8M | $-17.7M | $-14.3M | $-14.0M | $-7.0M | $-6.9M | $-2.2M | $-1.3M |
| Returns | |||||||||||
| ROE | -203.8% | -203.8% | -1303.0% | -416.1% | -106.6% | -50.1% | -58.0% | -352.4% | -139.3% | -773.3% | -254.3% |
| Valuation | |||||||||||
| P/B | 0.09 | 0.09 | 2.07 | 87.42 | 153.93 | — | — | — | — | — | — |
| Growth & Yield | |||||||||||
| EPS Growth | 93.5% | 93.5% | -1083.0% | 97.7% | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-95.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-266.89 → -17.40
Residual
-95.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.